Company / Cash & Equivalents
AbbVie Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$5.2B
FY2025
5-year range
$5.2B / $12.8B
FY2021-FY2025
Trend
-5.3%
vs FY2024
Sector context
#7 of 209
Health Care
What the data says
Among 209 Health Care companies, AbbVie is in the top 3% for cash & equivalents. Cash & Equivalents has fluctuated over the past 10 years, ranging from $5.1B in FY2016 to $39.9B in FY2019.
Based on SEC 10-K filings.
$5.2B in FY2025 with a 5-year CAGR of -9.2%. Top quartile in the Health Care sector.
Declined from $12.8B to $5.2B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -17.2%
- 5-Year CAGR
- -9.2%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 209This company $5.2B Sector average $696.0M
▼
+651.3% above sector average
Key checks
Key Insights
- 5-year CAGR of -9.2%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 5.3% year-over-year.
- Ranks #7 out of 209 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score 0.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.2B | -5.3% |
| FY2024 | $5.5B | -56.9% |
| FY2023 | $12.8B | +39.3% |
| FY2022 | $9.2B | -5.6% |
| FY2021 | $9.7B | +15.4% |
| FY2020 | $8.4B | -78.8% |
| FY2019 | $39.9B | +447.7% |
| FY2018 | $7.3B | -21.6% |
| FY2017 | $9.3B | +82.4% |
| FY2016 | $5.1B | -39.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026